325 related articles for article (PubMed ID: 7037174)
21. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay.
Salmon SE; Meyskens FL; Alberts DS; Soehnlen B; Young L
Cancer Treat Rep; 1981; 65(1-2):1-12. PubMed ID: 7226159
[TBL] [Abstract][Full Text] [Related]
22. Bisantrene, an active new drug in the treatment of metastatic breast cancer.
Yap HY; Yap BS; Blumenschein GR; Barnes BC; Schell FC; Bodey GP
Cancer Res; 1983 Mar; 43(3):1402-4. PubMed ID: 6825109
[TBL] [Abstract][Full Text] [Related]
23. Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.
Von Hoff DD; Howser K; Gormley P; Bender RA; Glaubiger D; Levine AS; Young RC
Cancer Treat Rep; 1978 Oct; 62(10):1421-6. PubMed ID: 361222
[TBL] [Abstract][Full Text] [Related]
24. Phase I trial of dihydroxyanthracenedione.
Van Echo DA; Whitacre MY; Aisner J; Wiernik PH
Cancer Treat Rep; 1981; 65(9-10):831-4. PubMed ID: 7273015
[TBL] [Abstract][Full Text] [Related]
25. Phase I clinical and pharmacological study of 4'-(9-acridinylamino)-methanesulfon-m-anisidide using an intermittent biweekly schedule.
Van Echo DA; Chiuten DF; Gormley PE; Lichtenfeld JL; Scoltock M; Wiernik PH
Cancer Res; 1979 Oct; 39(10):3881-4. PubMed ID: 476624
[TBL] [Abstract][Full Text] [Related]
26. Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934).
LoRusso P; Foster BJ; Poplin E; McCormick J; Kraut M; Flaherty L; Heilbrun LK; Valdivieso M; Baker L
Clin Cancer Res; 1995 Dec; 1(12):1487-93. PubMed ID: 9815948
[TBL] [Abstract][Full Text] [Related]
27. Simultaneous paclitaxel and radiotherapy: initial clinical experience in lung cancer and other malignancies.
Vogt HG; Martin T; Kolotas C; Schneider L; Strassmann G; Zamboglou N
Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-101-S12-105. PubMed ID: 9331131
[TBL] [Abstract][Full Text] [Related]
28. Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.
Kuhnt T; Becker A; Pigorsch S; Pelz T; Bloching M; Passmann M; Lotterer E; Hänsgen G; Dunst J
Strahlenther Onkol; 2003 Oct; 179(10):673-81. PubMed ID: 14566475
[TBL] [Abstract][Full Text] [Related]
29. Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer.
Kasturi VK; Dearing MP; Piscitelli SC; Russell EK; Sladek GG; O'Neil K; Turner GA; Morton TL; Christian MC; Johnson BE; Kelley MJ
Clin Cancer Res; 1998 Sep; 4(9):2095-102. PubMed ID: 9748125
[TBL] [Abstract][Full Text] [Related]
30. Phase I and clinical pharmacological evaluation of 4'-deoxydoxorubicin in patients with advanced cancer.
Stanton GF; Raymond V; Wittes RE; Schulman P; Budman D; Baratz R; Williams L; Petroni GR; Geller NL; Hancock C
Cancer Res; 1985 Apr; 45(4):1862-8. PubMed ID: 3978646
[TBL] [Abstract][Full Text] [Related]
31. Activation of tumor-cytostatic macrophages with the antitumor agent 9,10-anthracenedicarboxaldehyde bis[(4,5-dihydro-1H-imidazole-2-yl)hydrazone] dihydrochloride (bisantrene).
Wang BS; Lumanglas AL; Ruszala-Mallon VM; Durr FE
Cancer Res; 1984 Jun; 44(6):2363-7. PubMed ID: 6426780
[TBL] [Abstract][Full Text] [Related]
32. Phase I clinical and pharmacokinetic study of kahalalide F administered weekly as a 1-hour infusion to patients with advanced solid tumors.
Pardo B; Paz-Ares L; Tabernero J; Ciruelos E; García M; Salazar R; López A; Blanco M; Nieto A; Jimeno J; Izquierdo MA; Trigo JM
Clin Cancer Res; 2008 Feb; 14(4):1116-23. PubMed ID: 18281545
[TBL] [Abstract][Full Text] [Related]
33. Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer.
Takano M; Kikuchi Y; Kita T; Suzuki M; Ohwada M; Yamamoto T; Yamamoto K; Inoue H; Shimizu K
Anticancer Res; 2002; 22(3):1833-8. PubMed ID: 12168878
[TBL] [Abstract][Full Text] [Related]
34. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
[TBL] [Abstract][Full Text] [Related]
35. A phase I and pharmacokinetic study of ILX-295501, an oral diarylsulfonylurea, on a weekly for 3 weeks every 4-week schedule in patients with advanced solid malignancies.
Forouzesh B; Takimoto CH; Goetz A; Diab S; Hammond LA; Smetzer L; Schwartz G; Gazak R; Callaghan JT; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2003 Nov; 9(15):5540-9. PubMed ID: 14654534
[TBL] [Abstract][Full Text] [Related]
36. Phase II evaluation of amsacrine (m-AMSA) in solid tumors, myeloma, and lymphoma: a University of Arizona and Southwest Oncology Group Study.
Ahmann FR; Meyskens FL; Jones SE; Bukowski RM; Saiers JH; Ryan DH; Costanzi J; Vaughn CB; Coltman CA
Cancer Treat Rep; 1983; 67(7-8):697-700. PubMed ID: 6688199
[TBL] [Abstract][Full Text] [Related]
37. Phase I study of a 5-day schedule of mitoxantrone (dihydroxyanthracenedione).
Wynert WR; Harvey HA; Lipton A; Schweitzer J; White DS
Cancer Treat Rep; 1982 Jun; 66(6):1303-6. PubMed ID: 7083234
[TBL] [Abstract][Full Text] [Related]
38. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer.
Eisen T; Thatcher N; Leyvraz S; Miller WH; Couture F; Lorigan P; Lüthi F; Small D; Tanovic A; O'Brien M
Lung Cancer; 2009 Apr; 64(1):60-5. PubMed ID: 18692272
[TBL] [Abstract][Full Text] [Related]
39. In vitro chemosensitivities of human tumor stem cells to the Phase II drug 4'-(9-acridinylamino)methanesulfon-m-anisidide and prospective in vivo correlations.
Ahmann FR; Meyskens FL; Moon TE; Durie BG; Salmon SE
Cancer Res; 1982 Nov; 42(11):4495-8. PubMed ID: 6897012
[TBL] [Abstract][Full Text] [Related]
40. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
